Therapeutic Advances in Gastroenterology (Sep 2020)
Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study
Abstract
Background: Mailed fecal immunochemical test (FIT) outreach effectively increases colorectal cancer (CRC) screening but is underutilized. This pilot aimed to determine the use of FIT for CRC screening among Medicare Advantage enrollees when offered via mailed outreach and the factors associated with FIT return. Methods: Our pilot study included Medicare Advantage enrollees who were 50–75-years old, not up to date with CRC screening, and had a billable primary care encounter in the prior 3 years. Eligible patients received a letter containing information about CRC screening and a FIT kit, screening status by FIT was then assessed using the electronic health record. Results: Of the 1142 patients identified, 945 were eligible for outreach. On 12-month follow up, 29% of patients ( n = 276) completed CRC screening via FIT, with a median return time of 140 days [interquartile range (IQR) 52–257]; 6% ( n = 17) of the completed tests were positive, and 53% ( n = 9) of patients have completed a diagnostic colonoscopy. Patients with primary encounter <12 months prior to mailed outreach were most likely to complete a FIT. Over the 12-month study period, CRC screening rates increased by 5% (63–68%). Conclusions: Mailed FIT outreach in a Medicare Advantage population was feasible and led to a 5% increase in CRC screening completion. Our pilot revealed rare incorrect patient addresses and high lab discard rate; both important factors that were addressed prior to larger-scale implementation of a mailed FIT program. Further research is needed to understand the potential impact of multilevel interventions on CRC screening in this healthcare system.